# Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers

> **NCT02203487** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIIF 1149 BS - single rising dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02203487
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2000-06
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203487, "Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02203487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*